SCHEMBL6693946

SCHEMBL6693946

CC(=O)O[C@@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
AR P10275 7/20 0.67
NR3C1 P04150 6/20 0.67
PGR P06401 6/20 0.67
CYP3A4 P08684 6/20 0.67
LMNA P02545 5/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
CYP2C9 P11712 3/20 0.67
MAPK1 P28482 3/20 0.67
NPSR1 Q6W5P4 3/20 0.67
HIF1A Q16665 2/20 0.67
ABCB11 O95342 2/20 0.67
POLB P06746 1/20 0.67
PDE4D Q08499 1/20 0.56
CYP19A1 P11511 2/20 0.56
ALDH1A1 P00352 3/20 0.56
CHRM2 P08172 3/20 0.56
CHRM1 P11229 3/20 0.56
USP2 O75604 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6693949 1.00 MEN1 (0.68) MEN1KMT2AARNR3C1PGR
Delmadinone Acetate SCHEMBL146081 0.89 NR3C1 (0.68) MEN1KMT2AARNR3C1PGR
Delmadinone Acetate SCHEMBL146080 0.89 NR3C1 (0.68) MEN1KMT2AARNR3C1PGR
SCHEMBL7196456 0.83 PGR (0.65) MEN1KMT2AARNR3C1PGR
SCHEMBL8859696 0.82 MEN1 (0.69) MEN1KMT2AARNR3C1PGR
SCHEMBL9169846 0.81 MEN1 (1.00) MEN1KMT2AARNR3C1PGR
Megestrol Acetate SCHEMBL8817569 0.80 AR (1.00) MEN1KMT2AARNR3C1PGR
Megestrol Acetate SCHEMBL13941350 0.80 AR (1.00) MEN1KMT2AARNR3C1PGR
Megestrol Acetate SCHEMBL21281326 0.80 AR (1.00) MEN1KMT2AARNR3C1PGR
Megestrol Acetate SCHEMBL745 0.80 AR (1.00) MEN1KMT2AARNR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082556-A1 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use ENDORECHERCHE, INC. 2004-04-29 US disclosed
EP-1321146-A2 Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use Endorecherche Inc. (CA) 2003-06-25 EP disclosed
US-6541463-B1 17-spirolactone derivatives of steroids ENDORECHERCHE, INC. (CA) 2003-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082556-A1 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use HSD17B11, HSD17B3, HSD17B1 MEN1 1907/4885KMT2A 3178/4885AR 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.